Loading ...
expanding its research partnership with Rocheto discovernew formulations of fusion inhibitors
As part of the Roche - Trimeris agreement , researchers at both companies will be tryingto discovernext generation peptides ( fusion inhibitors
by the removal of fusion proteins from the cell surface(passive) is caused byfusion inhibition
by the removal of fusion proteins from the cell surface(passive) is causedfusion inhibition
a major effortto designsmall molecule inhibitors of fusion
to block the substances ( proteins ) that lead to that growth , which include vascular endothelial growth factor ( VEGF ) and placental growth factor(passive) are designedAngiogenesis inhibitors
to prevent the virus from docking to the cell(passive) are designedfusion inhibitors
from a variety of sources(passive) have been discoveredAngiogenesis inhibitors
to stop tumours growing by cutting off their blood supply(passive) are designedAngiogenesis inhibitors
Approachesto discoverHsp90 inhibitors
from natural sources , including : tree bark , fungi , shark muscle and cartilage , sea coral , green tea and herbs(passive) have been discoveredAngiogenesis inhibitors
to target cancers that already have existing defects in DNA repairs(passive) are designedPARP inhibitors
effortsto discovernonpeptide inhibitors
Coadministration of desloratadine withresultsCYP3A4 inhibitors
to prevent cancer cells from repairing their damaged DNA(passive) are designedPARP inhibitors
to kill cancer cells by exploiting defects in a tumor DNA repair pathway(passive) are designedPARP inhibitors
to specifically treat tumors with faulty BRCA1 and BRCA2 genes in breast and ovarian cancers(passive) have been designed PARP inhibitors
to specifically treat tumors with faulty BRCA1 and BRCA2 genes in breast and ovarian cancers(passive) have been designedPARP inhibitors
inactivation of SLFN11(passive) caused byPARP inhibitors
to treat patients with persistently high LDL - C levels despite optimal use of statins(passive) are designedPCSK9 inhibitors
to slow the inactivation of incretin hormones GLP-1(passive) are designedDPP-4 inhibitors
Dr. el Kouni 's group(passive) designed byuridine phosphorylase inhibitors
ongoing effortsto designRPA70N inhibitors
which used covalent docking techniquesto prospectively discoverJAK3 inhibitors
mainly ... low levels of insulin secretion(passive) is caused ... byDPP-4 inhibitors
a targeted programto discoverPARG inhibitors
to overcome some of the drawbacks of 17AAG , including limited oral bioavailability and solubility(passive) may be designedHSP90 inhibitors
to work with the statin class of cholesterol - reducing drugs(passive) are designedPLA2 inhibitors
by the insertion of viral proteins into the membrane(passive) are ... caused byFusion
to stop the repair process in cancer cells , leaving the damaged cells to die(passive) are designedPARP inhibitors
heat enoughto causefusion
enough heatto causefusion
inflammation in the spine and other joints andcausesfusion
Another styleledFusion
a stream of hydrogen plasma ... enoughto causefusion
to mix complete DJ sets from ... creativity and shape your music in a million ways(passive) is designedFusion
The heat ... sufficientto causefusion
It takes energyto causefusion
Jazz Miles Davisessentially inventedFusion
The processcausingfusion
to block HIV from entering blood cellsare designedto block HIV from entering blood cells
to stop the virus from getting into cells in the first placedesignedto stop the virus from getting into cells in the first place
with anti - HIV potencydesignedwith anti - HIV potency
in an antiviral effect without short - term toxicitycould resultin an antiviral effect without short - term toxicity
in an increase in fentanyl plasma concentrations , which could increase or prolong both the therapeutic and adverse effectsmay resultin an increase in fentanyl plasma concentrations , which could increase or prolong both the therapeutic and adverse effects
to the development of new antiviral agentscould leadto the development of new antiviral agents
tumor growth inhibition but no tumor regressioncausetumor growth inhibition but no tumor regression
to substantial increases in trazodone plasma concentrations with the potentialmay leadto substantial increases in trazodone plasma concentrations with the potential
transient activation of the protein kinase clients they are chaperoning ... resulting in initiation of signal transduction and significant physiological events in both tumor and tumor microenvironmentcan ... causetransient activation of the protein kinase clients they are chaperoning ... resulting in initiation of signal transduction and significant physiological events in both tumor and tumor microenvironment
possiblymay ... leadpossibly
to increased concentration of solifenacin succinateleadingto increased concentration of solifenacin succinate
a rashcan causea rash
The rash(passive) caused byThe rash
rash(passive) caused byrash
diarrhea and other gastrointestinal toxicitycausediarrhea and other gastrointestinal toxicity
D1 reduction(passive) caused byD1 reduction
transient activation of the protein kinase clients they are chaperoningcan ... causetransient activation of the protein kinase clients they are chaperoning
oftencauseoften
a number ofcan causea number of
when used aloneresultwhen used alone
The third generation(passive) are designedThe third generation
the AQP2 membrane accumulation(passive) caused bythe AQP2 membrane accumulation
to treat respiratory syncytial virusdesignedto treat respiratory syncytial virus
Prevention of acneiform rash(passive) caused byPrevention of acneiform rash
and carried out all cell - fusion assays , interpreted datadesignedand carried out all cell - fusion assays , interpreted data
in generally cutaneous toxicityresultin generally cutaneous toxicity
AfEs(passive) caused byAfEs
in a number viagraresultedin a number viagra
in decreased anti - tumor responses ... regardless of upregulation of HLA - DR expression on the tumor cellresultedin decreased anti - tumor responses ... regardless of upregulation of HLA - DR expression on the tumor cell
to target mutated forms of EGFR ( Galvani et al . , 2015designedto target mutated forms of EGFR ( Galvani et al . , 2015
to significantly more rapid declines in HIV viral load ( VLleadto significantly more rapid declines in HIV viral load ( VL
by interfering the N - terminal website ATP binding site of HSP90causeby interfering the N - terminal website ATP binding site of HSP90
to inhibit leukemia cell proliferationresultingto inhibit leukemia cell proliferation
in an inability to handle immunoglobulin production with the induction of the UPR and myeloma cell deathwould resultin an inability to handle immunoglobulin production with the induction of the UPR and myeloma cell death
to overall EGFR amounts to lessen above timeleadto overall EGFR amounts to lessen above time
significantly more rapid declines in HIV viral load ( VL ) than all other ART classescausesignificantly more rapid declines in HIV viral load ( VL ) than all other ART classes
problemsmight causeproblems
the sebaceous glands connected to hair follicles to increase production of inflammatory mediatorscan leadthe sebaceous glands connected to hair follicles to increase production of inflammatory mediators
reduced or absent FNR - RFP , an apicoplast markercausereduced or absent FNR - RFP , an apicoplast marker
introducing common versus uncommon mutations as stratification factor in the randomization schemadesignedintroducing common versus uncommon mutations as stratification factor in the randomization schema